All in all, it was a cordial and friendly meeting that further thawed ice between the two countries. Helping this process is probably the longevity of Abe’s tenure and hold on power. Some believe that he is going for an unprecedented third term in office and has already been re-elected as the leader of the ruling Liberal Democratic Party (one of the longest reigning parties in the world). It helps to have a strong leader in power in order to deal with a powerful strongman like Putin who skirted around the constitution by temporarily stepping down from Prime Minister-ship only to return to power as the President.

        Government authorities in the U.S., at the federal, state, and local level, and in other countries and jurisdictions, including the E.U. and Japan, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the U.S. and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.

The functional currency of the Company and its subsidiaries is in U.S dollar (the “dollar”), because the dollar is the currency of the primary economic environment in which the Company and its subsidiaries operate, and expect to continue operating in the foreseeable future. Transactions and balances denominated in dollars are presented in their original amounts. Non-dollar denominated transactions and balances have been re-measured to dollars in accordance with the provisions of ASC 830-10, “Foreign Currency Translation.” All transaction gains and losses from re-measurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statement of operations as financial income or expenses, as appropriate.

As of December 31, 2018, we had twenty-one employees, of which seventeen were full-time employees and four were part-time employees. Fifteen of the Company’s employees were involved in our clinical and product development operations and six served in general and administrative capacities.

Hanuš, J., Ceccone, G. & Rossi, F. Amino-rich plasma polymer films prepared by RF magnetron sputtering. Plasma Process. Polym. 9, 371–379 (2012).

Data are represented as the mean ± SEM of at least three independent experiments. Statistical analysis was performed using Student’s t-test or one-way ANOVA as appropriate. P < 0.05 was considered significant.

As of December 31, 2018, 16.994 restricted stock units (RSUs) granted to our Office Holders as a group were outstanding. For outstanding equity-based awards granted to our Office Holders, see below under “Item 6. Directors, Senior Management and Employees—E. Share Ownership—Certain Information Concerning Equity Awards to Office Holders.”

Cerbai, E. et al. Characterization of the hyperpolarization-activated current, I(f), in ventricular myocytes from human failing heart. Circulation 95, 568–71 (1997).

I studied Zen for fifteen years, and still have an interest in philosophy, particularly the eastern ones, and also stoicism. But I do resent how Zen has been used by modern culture and even used as an excuse to embrace death. A Zen monk would live an austere existence, but with a rich inner life. In many ways a recipe for a healthy, long and happy life.

Catalent announces investment for its Zydis ODT technology, offering increased drug load and taste-masking capabilities.

including the treatment of patients with R885H/C mutations, a population of PNH patients that does not respond to currently approved therapies. Importantly, zilucoplan also blocks interaction of C5b with C6 and the formation of the MAC. For more information, see the figure in the section titled "The Complement System." We believe this feature of directly blocking MAC assembly would be a differentiating property of zilucoplan that may be beneficial to patients in hypercoagulative and inflammatory states, such as infection, sepsis, and trauma.

Licensing revenue amounted to $2.0 million during the year ended December 31, 2018, compared to $1.1 million of revenue for the year ended December 31, 2017. The above-mentioned revenue resulted from the amortization of the upfront payment and a $1.5 million milestone payment received under the Samil Agreement.